# Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

> **NCT03203369** · PHASE1 · TERMINATED · sponsor: **Cellectis S.A.** · enrollment: 1 (actual)

## Conditions studied

- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

## Interventions

- **BIOLOGICAL:** UCART123

## Key facts

- **NCT ID:** NCT03203369
- **Lead sponsor:** Cellectis S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-28
- **Primary completion:** 2019-06-27
- **Final completion:** 2019-06-27
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03203369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03203369, "Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03203369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*